Skip to main content

Table 1 Exclusion ciriteria

From: Pre-Study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis

Previous ERCP
Known allergy or intolerance to one of the compounds used in the study
Participation in another interventional trial during the previous four weeks
Pregnancy and breast feeding
current acute pancreatitis
Renal insufficiency ≥ stage 4 (K/DOQI), i.e. MDRD-GFR < 30 ml/min/1,73 m2)
Hyperthyroidism
Symptomatic bradycardia <35 bpm
Atrioventricular block > 1° or other cardial conduction defects
Myasthenia gravis
Liver cirrhosis Child C
Overt coagulopathy
Kidney stone diathesis (calcium-magnesium-ammonium-phosphate stones)
Mental impairment, addiction or other disorders leading to the patients inability to understand the scope and possible consequences of a participation in a clinical trial
Magnesium medication within 14 days before the procedure
Inability to give informed consent